The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
Paula I. González-Ericsson(Breast Cancer Research Foundation)
Cited by 223
Related Papers
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis
|Nature Cancer|2022|114
Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC
|Journal of Thoracic Oncology|2021|33